Differential blood-based biomarkers of psychopathological dimensions of schizophrenia;Biomarcadores sanguíneos diferenciales de las dimensiones psicopatológicas de la esquizofrenia

Revista de Psiquiatria y Salud Mental

Volumn 9, Issue 4, 2016, Pages 219-227

  Garcia Alvarez, Leticia ^a,b,c   Garcia Portilla, Maria Paz ^a,b,c,d   Gonzalez Blanco, Leticia ^c,d   Saiz Martinez, Pilar Alejandra ^a,b,c,d   de la Fuente Tomas, Lorena ^c   Menendez Miranda, Isabel ^c,d   Iglesias, Celso ^c,d   Bobes, Julio ^a,b,c,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b Instituto de Neurociencias del Principado de Asturias (INEUROPA)   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

^d Servicio de Salud del Principado de Asturias (SESPA)   (Spain)

Author keywords

Biomarkers; Cognition; Negative symptoms; Positive symptoms; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

DIFFERENTIAL DIAGNOSIS; ENDOCRINE DISEASE; HUMAN; INFLAMMATION; MENTAL DISEASE; METABOLIC DISORDER; SCHIZOPHRENIA; SHORT SURVEY; BLOOD; COGNITION; COMPLICATION; DEPRESSION; PSYCHOLOGY;

BIOMARKERS; COGNITION; DEPRESSION; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84994071251     PISSN: 18889891     EISSN: 19894600     Source Type: Journal    
DOI: 10.1016/j.rpsm.2016.04.003     Document Type: Short Survey

References (117)

1. 1 Van Os, J., Kapur, S., Schizophrenia. Lancet. 374 (2009), 635–645.
2. 2 Wittchen, H.U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 21 (2011), 655–679.
3. 3 Chan, M.K., Gottschalk, M.G., Haenisch, F., Tomasik, J., Ruland, T., Rahmoune, H., et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Progr Neurobiol. 122 (2014), 45–72.
4. 4 Insel, T.R., The NIMH Research Domain Criteria (RDoC) Project: Precision medicine for psychiatry. Am J Psychiatry. 171 (2014), 395–397.
5. 5 Andreasen, N.C., Scale for the Assessment of Positive Symptoms. 1984, University of Iowa, Iowa City, IA.
6. 6 Kay, S.R., Fiszbein, A., Opler, L.A., The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 13 (1987), 261–276.
7. 7 Peralta, V., Cuesta, M.J., Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatry Res. 53 (1994), 31–40.
8. 8 Peralta, V., Cuesta, M.J., Validación de la Escala de los Síndromes Positivo y Negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso Esp Neurol Psiquiatr. 22 (1994), 171–177.
9. 9 Solberg, D.K., Bentsen, H., Refsum, H., Andreassen, O.A., Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia. Acta Psychiatr Scand. 132 (2015), 293–300.
10. 10 Zhang, X.Y., Chen, D.C., Tan, Y.L., An, H.M., Zunta-Soares, G.B., Huang, X.F., et al. Glucose disturbances in first-episode drug-naive schizophrenia: Relationship to psychopathology. Psychoneuroendocrinology. 62 (2015), 376–380.
11. 11 Meltzer, H.Y., Perry, E., Jayathilake, K., Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res. 59 (2003), 19–27.
12. 12 Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol Psychiatry. 70 (2011), 663–671.
13. 13 Drexhage, R.C., van der Heul-Nieuwenhuijsen, L., Padmos, R.C., van Beveren, N., Cohen, D., Versnel, M.A., et al. Inflammatory gene expression in monocytes of patients with schizophrenia: Overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol. 13 (2010), 1369–1381.
14. 14 Kurian, S.M., Le-Niculescu, H., Patel, S.D., Bertram, D., Davis, J., Dike, C., et al. Identification of blood biomarkers for psychosis using convergent functional genomics. Mol Psychiatry. 16 (2011), 37–58.
15. 15 Dimitrov, D.H., Lee, S., Yantis, J., Valdez, C., Paredes, R.M., Braida, N., et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: Potential role for IL-17 pathway. Schizophr Res. 151 (2013), 29–35.
16. 16 Erbagci, A.B., Herken, H., Koyluoglu, O., Yilmaz, N., Tarakcioglu, M., Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm. 10 (2001), 109–115.
17. 17 Hope, S., Ueland, T., Steen, N.E., Dieset, I., Lorentzen, S., Berg, A.O., et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res. 145 (2013), 36–42.
18. 18 Takahashi, M., Hayashi, H., Watanabe, Y., Sawamura, K., Fukui, N., Watanabe, J., et al. Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophr Res. 119 (2010), 210–218.
19. 19 Fernandes, B.S., Steiner, J., Bernstein, H.G., Dodd, S., Pasco, J.A., Dean, O.M., et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: Meta-analysis and implications. Mol Psychiatry. 21 (2016), 554–564.
20. 20 Giuffrida, A., Leweke, F.M., Gerth, C.W., Schreiber, D., Koethe, D., Faulhaber, J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 29 (2004), 2108–2114.
21. 21 Overall, J.E., Gorham, D.R., The Brief Psychiatric Rating Scale. Psychol Rep. 10 (1962), 790–812.
22. 22 Andreasen, N.C., Scale for the Assessment of Negative Symptoms. 1983, University of Iowa, Iowa City, IA.
23. 23 Marder, S.R., Davis, J.M., Chouinard, G., The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry. 58 (1997), 538–546.
24. 24 García-Portilla, M.P., Bobes, J., The new challenge in identifying the negative syndrome of schizophrenia. Rev Psiquiatr Salud Ment. 6 (2013), 141–143.
25. 25 Garcia-Portilla, M.P., Garcia, L., Saiz, P.A., Al-Halabi, S., Bobes-Bascaran, T., Bascaran, M.T., et al. Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 265 (2015), 559–566.
26. 26 Rabinowitz, J., Werbeloff, N., Caers, I., Mandel, F.S., Stauffer, V., Menard, F., et al. Negative symptoms in schizophrenia–The remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophr Res. 150 (2013), 334–338.
27. 27 Kirkpatrick, B., Fenton, W., Carpenter, W., Marder, S.R., The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 32 (2006), 296–303.
28. 28 Gard, D.E., Kring, A.M., Germans, G.M., Horan, W.P., Green, M.F., Anhedonia in schizophrenia: Distinction between anticipatory and consummatory pleasure. Schizophr Res. 93 (2007), 253–260.
29. 29 Foussias, G., Remington, G., Negative symptoms in schizophrenia: Avolition and Occam's razor. Schizophr Bull. 36 (2010), 359–369.
30. 30 Kring, A.M., Gur, R.E., Blanchard, J.J., Horan, W.P., Reise, S.P., The Clinical Assessment Interview for Negative Symptoms (CAINS): Final development and validation. Am J Psychiatry. 170 (2013), 165–172.
31. 31 Kirkpatrick, B., Strauss, G.P., Nguyen, L., Fischer, B.A., Daniel, D.G., Cienfuegos, A., et al. The Brief Negative Symptom Scale: Psychometric properties. Schizophr Bull. 37 (2011), 300–305.
32. 32 Rao, M.L., Kolsch, H., Effects of estrogen on brain development and neuroprotection–Implications for negative symptoms in schizophrenia. Psychoneuroendocrinology. 28:Suppl 2 (2003), 83–96.
33. 33 Kaneda, Y., Ohmori, T., Relation between estradiol and negative symptoms in men with schizophrenia. J Neuropsychiatry Clin Neurosci. 17 (2005), 239–242.
34. 34 Rothermundt, M., Ponath, G., Glaser, T., Hetzel, G., Arolt, V., S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology. 29 (2004), 1004–1011.
35. 35 Sethom, M.M., Fares, S., Bouaziz, N., Melki, W., Jemaa, R., Feki, M., et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 83 (2010), 131–136.
36. 36 Chen, S.F., Hu, T.M., Lan, T.H., Chiu, H.J., Sheen, L.Y., Loh, E.W., Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: Severe negative syndrome may be related to a distinct lipid pathophysiology. Eur Psychiatry. 29 (2014), 167–171.
37. 37 Procyshyn, R.M., Wasan, K.M., Thornton, A.E., Barr, A.M., Chen, E.Y., Pomarol-Clotet, E., et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci. 32 (2007), 331–338.
38. 38 Sicras-Mainar, A., Maurino, J., Ruiz-Beato, E., Navarro-Artieda, R., Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat. 11 (2015), 51–57.
39. 39 Ryan, M.C., Collins, P., Thakore, J.H., Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 160 (2003), 284–289.
40. 40 Spelman, L.M., Walsh, P.I., Sharifi, N., Collins, P., Thakore, J.H., Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 24 (2007), 481–485.
41. 41 Wani, R.A., Dar, M.A., Margoob, M.A., Rather, Y.H., Haq, I., Shah, M.S., Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. J Neurosci Rural Pract. 6 (2015), 17–22.
42. 42 Kirkpatrick, B., Fernandez-Egea, E., Garcia-Rizo, C., Bernardo, M., Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophr Res. 107 (2009), 122–127.
43. 43 Liu, Y.R., Hu, T.M., Lan, T.H., Chiu, H.J., Chang, Y.H., Chen, S.F., et al. Association of the PPAR-gamma gene with altered glucose levels and psychosis profile in schizophrenia patients exposed to antipsychotics. Psychiatry Investig. 11 (2014), 179–185.
44. 44 Newcomer, J.W., Riney, S.J., Vinogradov, S., Csernansky, J.G., Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. Psychiatry Res. 41 (1992), 191–202.
45. 45 Jose, J., Nandeesha, H., Kattimani, S., Meiyappan, K., Sarkar, S., Sivasankar, D., Association between prolactin and thyroid hormones with severity of psychopathology and suicide risk in drug free male schizophrenia. Clin Chim Acta. 444 (2015), 78–80.
46. 46 Akhondzadeh, S., Rezaei, F., Larijani, B., Nejatisafa, A.A., Kashani, L., Abbasi, S.H., Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res. 84 (2006), 405–410.
47. 47 Meyer, U., Schwarz, M.J., Müller, N., Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 132 (2011), 96–110.
48. 48 Miller, B.J., Culpepper, N., Rapaport, M.H., C-reactive protein levels in schizophrenia: A review and meta-analysis. Clin Schizophr Relat Psychoses. 7 (2014), 223–230.
49. 49 Singh, B., Chaudhuri, T.K., Role of C-reactive protein in schizophrenia: An overview. Psychiatry Res. 216 (2014), 277–285.
50. 50 Fan, X., Pristach, C., Liu, E.Y., Freudenreich, O., Henderson, D.C., Goff, D.C., Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 149 (2007), 267–271.
51. 51 Fawzi, M.H., Fawzi, M.M., Said, N.S., C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 190 (2011), 91–97.
52. 52 Zisook, S., Nyer, M., Kasckow, J., Golshan, S., Lehman, D., Montross, L., Depressive symptom patterns in patients with chronic schizophrenia and subsyndromal depression. Schizophr Res. 86 (2006), 226–233.
53. 53 Rocca, P., Bellino, S., Calvarese, P., Marchiaro, L., Patria, L., Rasetti, R., et al. Depressive and negative symptoms in schizophrenia: Different effects on clinical features. Compr Psychiatry. 46 (2005), 304–310.
54. 54 Jones, J.S., Stein, D.J., Stanley, B., Guido, J.R., Winchel, R., Stanley, M., Negative and depressive symptoms in suicidal schizophrenics. Acta Psychiatr Scand. 89 (1994), 81–87.
55. 55 Fialko, L., Freeman, D., Bebbington, P.E., Kuipers, E., Garety, P.A., Dunn, G., et al. Understanding suicidal ideation in psychosis: Findings from the Psychological Prevention of Relapse in Psychosis (PRP) trial. Acta Psychiatr Scand. 114 (2006), 177–186.
56. 56 Addington, D., Addington, J., Schissel, B., A depression rating scale for schizophrenics. Schizophr Res. 3 (1990), 247–251.
57. 57 Hamilton, M., A rating scale for depression. J Neurol Neurosurg Psychiatry. 23 (1960), 56–62.
58. 58 Chiappelli, J., Rowland, L.M., Wijtenburg, S.A., Muellerklein, F., Tagamets, M., McMahon, R.P., et al. Evaluation of myo-inositol as a potential biomarker for depression in schizophrenia. Neuropsychopharmacology. 40 (2015), 2157–2164.
59. 59 Noto, C.S., Gadelha, A., Belangero, S.I., Smith, M.A., de Aguiar, B.W., Panizzuti, B., et al. Association of biomarkers and depressive symptoms in schizophrenia. Neurosci Lett. 505 (2011), 282–285.
60. 60 Shrivastava, S., Pucadyil, T.J., Paila, Y.D., Ganguly, S., Chattopadhyay, A., Chronic cholesterol depletion using statin impairs the function and dynamics of human serotonin(1A) receptors. Biochemistry. 49 (2010), 5426–5435.
61. 61 Ergün, U.G., Uguz, S., Bozdemir, N., Güzel, R., Burgut, R., Saatçi, E., et al. The relationship between cholesterol levels and depression in the elderly. Int J Geriatr Psychiatry. 19 (2004), 291–296.
62. 62 Suttajit, S., Pilakanta, S., Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia. Neuropsychiatr Dis Treat. 9 (2013), 941–946.
63. 63 Ford, D.E., Erlinger, T.P., Depression and C-reactive protein in US adults: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 164 (2004), 1010–1014.
64. 64 Wen, S., Cheng, M., Wang, H., Yue, J., Li, G., Zheng, L., et al. Serum uric acid levels and the clinical characteristics of depression. Clin Biochem. 45 (2012), 49–53.
65. 65 Bioque, M., Garcia-Bueno, B., Macdowell, K.S., Meseguer, A., Saiz, P.A., Parellada, M., et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology. 38 (2013), 2568–2577.
66. 66 Elvevag, B., Goldberg, T.E., Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 14 (2000), 1–21.
67. 67 Green, M.F., Kern, R.S., Braff, D.L., Mintz, J., Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the right stuff?. Schizophr Bull. 26 (2000), 119–136.
68. 68 Dickinson, D., Iannone, V.N., Wilk, C.M., Gold, J.M., General and specific cognitive deficits in schizophrenia. Biol Psychiatry. 55 (2004), 826–833.
69. 69 Green, M.F., Kern, R.S., Heaton, R.K., Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res. 72 (2004), 41–51.
70. 70 Heinrichs, R.W., Zakzanis, K.K., Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology. 12 (1998), 426–445.
71. 71 Lewis, R., Should cognitive deficit be a diagnostic criterion for schizophrenia?. J Psychiatry Neurosci. 29 (2004), 102–113.
72. 72 Rund, B.R., Melle, I., Friis, S., Johannessen, J.O., Larsen, T.K., Midboe, L.J., et al. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr Res. 91 (2007), 132–140.
73. 73 Cornblatt, B.A., Lenzenweger, M.F., Dworkin, R.H., Erlenmeyer-Kimling, L., Childhood attentional dysfunctions predict social deficits in unaffected adults at risk for schizophrenia. Br J Psychiatry. 161:Suppl 18 (1992), 59–64.
74. 74 Harvey, P.D., When does cognitive decline occur in the period prior to the first episode of schizophrenia?. Psychiatry (Edgmont). 6 (2009), 12–14.
75. 75 Finkelstein, J.R., Cannon, T.D., Gur, R.E., Gur, R.C., Moberg, P., Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J Abnorm Psychol. 106 (1997), 203–212.
76. 76 Bilder, R.M., Goldman, R.S., Robinson, D., Reiter, G., Bell, L., Bates, J.A., et al. Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry. 157 (2000), 549–559.
77. 77 Goldberg, T.E., Gold, J.M., Greenberg, R., Griffin, S., Schulz, S.C., Pickar, D., et al. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry. 150 (1993), 1355–1362.
78. 78 Asarnow, R.F., Nuechterlein, K.H., Subotnik, K.L., Fogelson, D.L., Torquato, R.D., Payne, D.L., et al. Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-deficit/hyperactivity disorder: The University of California, Los Angeles Family Study. Arch Gen Psychiatry. 59 (2002), 1053–1060.
79. 79 Cannon, T.D., Zorrilla, L.E., Shtasel, D., Gur, R.E., Gur, R.C., Marco, E.J., et al. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry. 51 (1994), 651–661.
80. 80 Fioravanti, M., Carlone, O., Vitale, B., Cinti, M.E., Clare, L., A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev. 15 (2005), 73–95.
81. 81 Achim, A.M., Lepage, M., Episodic memory-related activation in schizophrenia: Meta-analysis. Br J Psychiatry. 187 (2005), 500–509.
82. 82 Ranganath, C., Minzenberg, M.J., Ragland, J.D., The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry. 64 (2008), 18–25.
83. 83 Laws, K.R., A meta-analytic review of Wisconsin Card Sort studies in schizophrenia: General intellectual deficit in disguise?. Cogn Neuropsychiatry. 4 (1999), 1–30.
84. 84 Lee, J., Park, S., Working memory impairments in schizophrenia: A meta-analysis. J Abnorm Psychol. 114 (2005), 599–611.
85. 85 Barch, D.M., Smith, E., The cognitive neuroscience of working memory: Relevance to CNTRICS and schizophrenia. Biol Psychiatry. 64 (2008), 11–17.
86. 86 Keefe, R.S., Fenton, W.S., How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr Bull. 33 (2007), 912–920.
87. 87 Tandon, R., Keshavan, M.S., Nasrallah, H.A., Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 102 (2008), 1–18.
88. 88 Fogelson, D.L., Nuechterlein, K.H., Asarnow, R.F., Payne, D.L., Subotnik, K.L., Validity of the family history method for diagnosing schizophrenia, schizophrenia-related psychoses, and schizophrenia-spectrum personality disorders in first-degree relatives of schizophrenia probands. Schizophr Res. 68 (2004), 309–317.
89. 89 Harvey, P.D., Sharma, T., Understanding and treating cognition in schizophrenia. A clinician's handbook. 2002, Martin Dunitz, London.
90. 90 Nuechterlein, K.H., Green, M.F., Kern, R.S., Baade, L.E., Barch, D.M., Cohen, J.D., et al. The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am J Psychiatry. 165 (2008), 203–213.
91. 91 Keefe, R.S., Goldberg, T.E., Harvey, P.D., Gold, J.M., Poe, M.P., Coughenour, L., The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 68 (2004), 283–297.
92. 92 Purdon, S.E., The Screen for Cognitive Impairment in Psychiatry (SCIP): Instructions and three alternate forms. 2005, PNL Inc., Edmonton, Alberta.
93. 93 Tregellas, J.R., Smucny, J., Harris, J.G., Olincy, A., Maharajh, K., Kronberg, E., et al. Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia. Am J Psychiatry. 171 (2014), 549–556.
94. 94 Krakowski, M., Czobor, P., Cholesterol and cognition in schizophrenia: A double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res. 130 (2011), 27–33.
95. 95 Hibbeln, J.R., Umhau, J.C., George, D.T., Shoaf, S.E., Linnoila, M., Salem, N., Plasma total cholesterol do not predicts CSF neurotransmitter metabolites. Am J Clin Nutr. 71:Suppl 1 (2000), 331–338.
96. 96 Lackner, N., Bengesser, S.A., Birner, A., Painold, A., Fellendorf, F.T., Platzer, M., et al. Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. World J Biol Psychiatry, 2015, 1–12.
97. 97 Leung, C.M., Stone, W.S., Lee, E.H., Seidman, L.J., Chen, E.Y., Impaired facilitation of self-control cognition by glucose in patients with schizophrenia: A randomized controlled study. Schizophr Res. 156 (2014), 38–45.
98. 98 Ribeiro-Santos, A., Lucio Teixeira, A., Salgado, J.V., Evidence for an immune role on cognition in schizophrenia: A systematic review. Curr Neuropharmacol. 12 (2014), 273–280.
99. 99 Martínez-Cengotitabengoa, M., Mac-Dowell, K.S., Leza, J.C., Micó, J.A., Fernandez, M., Echevarría, E., et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res. 137 (2012), 66–72.
100. 100 Nishi, A., Numata, S., Tajima, A., Kinoshita, M., Kikuchi, K., Shimodera, S., et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull. 40 (2014), 1154–1163.
101. 101 Muntjewerff, J.W., Kahn, R.S., Blom, H.J., den Heijer, M., Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: A meta-analysis. Mol Psychiatry. 11 (2006), 143–149.
102. 102 Prins, N.D., Den Heijer, T., Hofman, A., Koudstaal, P.J., Jolles, J., Clarke, R., et al. Homocysteine and cognitive function in the elderly: The Rotterdam Scan Study. Neurology. 59 (2002), 1375–1380.
103. 103 Hooshmand, B., Solomon, A., Kareholt, I., Rusanen, M., Hanninen, T., Leiviska, J., et al. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: A longitudinal study. J Intern Med. 271 (2012), 204–212.
104. 104 Moustafa, A.A., Hewedi, D.H., Eissa, A.M., Frydecka, D., Misiak, B., Homocysteine levels in schizophrenia and affective disorders-focus on cognition. Front Behav Neurosci., 8, 2014, 343.
105. 105 Levine, J., Stahl, Z., Sela, B.A., Ruderman, V., Shumaico, O., Babushkin, I., et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60 (2006), 265–269.
106. 106 Ayesa-Arriola, R., Pérez-Iglesias, R., Rodríguez-Sánchez, J.M., Mata, I., Gómez-Ruiz, E., García-Unzueta, M., et al. Homocysteine and cognition in first-episode psychosis patients. Eur Arch Psychiatry Clin Neurosci. 262 (2012), 557–564.
107. 107 Cabrera, B., Bioque, M., Penadés, R., González-Pinto, A., Parellada, M., Bobes, J., et al. Cognition and psychopathology in first-episode of psychosis: Are they related to inflammation?. Psychol Med, 2016, 1–12.
108. 108 Murray, H.J., O'Connor, J.J., A role for COX-2 and p38 mitogen activated protein kinase in long-term depression in the rat dentate gyrus in vitro. Neuropharmacology. 44 (2003), 374–380.
109. 109 Muller, N., Riedel, M., Schwarz, M.J., Engel, R.R., Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 255 (2005), 149–151.
110. 110 Zhang, X.Y., Chen da, C., Xiu, M.H., Tang, W., Zhang, F., Liu, L., et al. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr Res. 139 (2012), 66–72.
111. 111 Toyomoto, M., Ohta, M., Okumura, K., Yano, H., Matsumoto, K., Inoue, S., et al. Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures. FEBS Lett 562 (2004), 211–215.
112. 112 Schwarz, E., Guest, P.C., Rahmoune, H., Harris, L.W., Wang, L., Leweke, F.M., et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 17 (2012), 494–502.
113. 113 Schwarz, E., Izmailov, R., Spain, M., Barnes, A., Mapes, J.P., Guest, P.C., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights. 5 (2010), 39–47.
114. 114 Dickerson, F., Stallings, C., Origoni, A., Boronow, J., Yolken, R., C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 93 (2007), 261–265.
115. 115 Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Yolken, R., Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 150 (2013), 456–459.
116. 116 Micoulaud-Franchi, J.A., Faugere, M., Boyer, L., Fond, G., Richieri, R., Faget, C., et al. Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophr Res. 165 (2015), 94–96.
117. 117 Bioque, M., Cabrera, B., García-Bueno, B., Mac-Dowell, K.S., Torrent, C., Saiz, P.A., et al. Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. J Psychiatr Res. 75 (2016), 14–21.